CEO: Stephen R. Davis

Sector: Health Technology
Industry:Biotechnology

Exchange: NASDAQ

Country: US

Description: ACADIA Pharmaceuticals, Inc. operates as a biopharmaceutical company focused on the development and commercialization of medicines to address unmet medical needs in central nervous system, or CNS, disorders. The firms product include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company was founded by Mark R. Brann on July 16, 1993 and is headquartered in San Diego, CA.


Key numbers

Market Capitalization:6628768330
Shares Outstanding: 155861000
Float: 155562059
Next Earning Date:2020-08-05
TTm EPS: -1.5783
TTm Dividend Rate:
200 days moving average:45.13
50 days moving average: 49.63
One day percent Change: -2.17



2018-06-30, 2018-09-30, 2018-12-31, 2019-03-31,
2018-06-30, 2018-09-30, 2018-12-31, 2019-03-31,
2015-12-31, 2016-12-31, 2017-12-31, 2018-12-31,
2015-12-31, 2016-12-31, 2017-12-31, 2018-12-31,